

# CELEB: Lung volume reduction in COPD - surgery

<b>Submission date</b> 23/05/2016	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 23/05/2016	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 03/05/2023	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Chronic obstructive pulmonary disease (COPD) is the collective name for a group of diseases which affect the lungs. One of the diseases is emphysema, a lung condition in which the tiny air sacs (alveoli) in the lungs become damaged over time. In emphysema, the alveoli become overfilled with air, causing the walls to weaken and eventually burst, creating one larger air space instead of many small ones. This means that the sufferer is unable to breathe out fully, leading to breathlessness which becomes progressively worse. Lung volume reduction surgery (LVRS) is an operation in which the worst affected part of the lung is removed, making more space for the remaining healthier lung to function. There is good evidence that in properly selected individuals this can improve breathlessness and increase life expectancy. It is a major operation and does carry a risk of complications however. A more recent approach is to use a fiberoptic camera (bronchoscope) to place valves into the airways of the lung. These stop air from entering the worst-affected section of the lung causing it to collapse, leading to similar benefits of LVRS. The aim of this study is to compare the effectiveness of these two techniques in the treatment of patients with emphysema.

### Who can participate?

Adults with a heterogeneous pattern of emphysema (isolated to certain areas of the lungs and to a varying extent between segments of the lungs)

### What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group undergo lung volume reduction surgery. Those in the second group have endobronchial valves placed into their airways using a bronchoscope while they are sedated. One year after the procedures, participants in both groups undergo a number of physical tests to find out if their lung function has improved as well as their overall quality of life.

### What are the possible benefits and risks of participating?

Not provided at time of registration

### Where is the study run from?

1. Royal Brompton Hospital (UK)
2. Glenfield Hospital (UK)
3. St Bartholomew's Hospital (UK)

4. Northern General Hospital (UK)
5. Golden Jubilee National Hospital (UK)

When is the study starting and how long is it expected to run for?  
April 2016 to September 2020

Who is funding the study?  
National Institute for Health Research (UK)

Who is the main contact?  
Sara Buttery  
s.buttery@rbht.nhs.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Sara Buttery

**Contact details**  
Royal Brompton Hospital  
Fulham Road  
London  
United Kingdom  
SW3 6NP  
+44 (0)207 351 8029  
s.buttery@rbht.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
30523

## Study information

**Scientific Title**  
The CELEB trial: Comparative Effectiveness of Lung volume reduction surgery for Emphysema and

**Acronym**  
CELEB

**Study objectives**

The aim of this study is to evaluate the relative effectiveness and value of two options currently available for the treatment of COPD patients with a heterogeneous pattern of emphysema. These are lung volume reduction surgery (LVRS) and the bronchoscopic placement of endobronchial valves (BLVR).

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

London - Fulham Research Ethics Committee, 18/02/2016, ref: 16/LO/0286

**Study design**

Interventional; Design type: Treatment, Device, Surgery

**Primary study design**

Interventional

**Secondary study design**

Randomised parallel trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

**Health condition(s) or problem(s) studied**

Emphysema

**Interventions**

Patients will be randomised to either unilateral video assisted thoracoscopic (VATS) lung volume reduction surgery (LVRS) or endobronchial valves (BLVR) placed to achieve lobar occlusion.

**Intervention Type**

Device

**Primary outcome measure**

Change in iBODE score (a composite of BMI, FEV1, MRC dyspnoea score and shuttle walk test distance) one year post procedure.

**Secondary outcome measures**

1. Health related quality of life is measured using the COPD assessment test score (CAT)
2. Physical activity level
3. Change in residual volume (RV)
4. Fat free mass

**Overall study start date**

01/04/2016

**Completion date**

30/09/2020

## **Eligibility**

**Key inclusion criteria**

1. Adults (aged 18 or over) with COPD
2. FEV1 <60% predicted
3. Significant hyperinflation (TLC>100% predicted, RV>170% predicted)
4. Ex-smoker >3 months
5. MRC dyspnoea score 3 or more
6. CT scan assessed at MDT to have intact interlobar fissures (>90%) and heterogeneous emphysema
7. Provision of informed consent to participate

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

Planned Sample Size: 76; UK Sample Size: 76

**Total final enrolment**

88

**Key exclusion criteria**

1. Smoking within 3 months
2. CT scan shows interlobar fissures are not intact
3. Major comorbidity limiting survival
4. Significant pulmonary fibrosis
5. FEV1 and TLco <20%
6. PaO2 < 7.0kPa
7. PaO2 > 7kPa
8. Presence of interlobar collateral ventilation assessed by Chartis system

**Date of first enrolment**

01/06/2016

**Date of final enrolment**

01/06/2019

## **Locations**

### **Countries of recruitment**

England

Scotland

United Kingdom

### **Study participating centre**

#### **Royal Brompton Hospital**

Fulham Road

London

United Kingdom

SW3 6NP

### **Study participating centre**

#### **Glenfield Hospital**

University Hospitals Leicester

United Kingdom

LE3 9QP

### **Study participating centre**

#### **St Bartholomew's Hospital**

Barts Health NHS Foundation Trust

United Kingdom

EC1A 7BE

### **Study participating centre**

#### **Northern General Hospital**

Sheffield

United Kingdom

S5 7AU

### **Study participating centre**

#### **Golden Jubilee National Hospital**

Glasgow

United Kingdom

G81 4DY

# Sponsor information

## Organisation

Royal Brompton and Harefield NHS Foundation Trust

## Sponsor details

Fulham Road  
London  
England  
United Kingdom  
SW3 6NP

## Sponsor type

Hospital/treatment centre

## ROR

<https://ror.org/02218z997>

# Funder(s)

## Funder type

Government

## Funder Name

National Institute for Health Research

## Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

30/09/2021

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	17/10/2018	30/10/2019	Yes	No
<a href="#">Results article</a>		27/04/2023	03/05/2023	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No